

PKG / PRKG1 Antibody (aa657-671)

Rabbit Polyclonal Antibody Catalog # ALS16514

Specification

PKG / PRKG1 Antibody (aa657-671) - Product Information

Application IHC
Primary Accession Q13976
Other Accession 5592

Reactivity Human, Mouse, Rat, Rabbit, Monkey, Pig,

Chicken, Bovine, Horse, Dog

Host Rabbit Clonality Polyclonal

Isotype IgG
Calculated MW 76364

PKG / PRKG1 Antibody (aa657-671) - Additional Information

Gene ID 5592

Other Names

PRKG1, CGKI, CGMP kinase I, CGMP protein kinase type I, CGK-I, CGK1, PKGI, PKG I, PRKGR1B, PRKG1B, PRKGR1A, PGK, PKG, CGK, CGK 1, CGKI-alpha, CGKI-BETA

Target/Specificity

Recognizes human PKG1 alpha at ~75kD.

Reconstitution & Storage

PBS, pH 7.2, 50% glycerol, 0.09% azide. Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.

Precautions

PKG / PRKG1 Antibody (aa657-671) is for research use only and not for use in diagnostic or therapeutic procedures.

PKG / PRKG1 Antibody (aa657-671) - Protein Information

Name PRKG1

Synonyms PRKG1B, PRKGR1A, PRKGR1B

Function

Serine/threonine protein kinase that acts as a key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the





NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle.

Cellular Location

Cytoplasm. Note=Colocalized with TRPC7 in the plasma membrane.

Tissue Location

Primarily expressed in lung and placenta.


Volume 250 μl

PKG / PRKG1 Antibody (aa657-671) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

PKG / PRKG1 Antibody (aa657-671) - Images





Anti-PRKG1 / CGKI antibody IHC of human skeletal muscle.

PKG / PRKG1 Antibody (aa657-671) - Background

Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates MRVI1/IRAG and inhibits IP3- induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle.

PKG / PRKG1 Antibody (aa657-671) - References

Sandberg M., et al. FEBS Lett. 255:321-329(1989).
Sandberg M., et al. Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
Tamura N., et al. Hypertension 27:552-557(1996).
Orstavik S., et al. Genomics 42:311-318(1997).
Ota T., et al. Nat. Genet. 36:40-45(2004).